In head-to-head comparisons, patients on injectable semaglutide or injectable tirzepatide lost significantly more weight than those on oral semaglutide
Bee venom and its active component Melittin synergistically potentiate the anticancer effect of Sorafenib against HepG2 cells
Proton Pump Inhibitors, H2-Receptor Antagonists, Metformin, and Vitamin B-12 Deficiency: Clinical Implications
These can include, but are not limited to, pain, redness, or swelling at the place of injection
REDEFINE Trial Headlines Trial REDEFINE 1 Phase 3 Duration 68 weeks Population (N) 3,417 adults with obesity or overweight + 1 comorbidity, without T2D Key Result 20.4% mean weight change vs 3.0% placebo (treatment-policy)